With No Lysine Kinase 3 (WNK3); A Target Enabling Package 由 Pinkas, D

其他作者: “...Pinkas, D...”

With no lysine kinase 3 (WNK3); A Target Enabling Package 由 Pinkas, D

其他作者: “...Pinkas, D...”

Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors 由 Suebsuwong, C, Pinkas, D, Ray, S, Bufton, J, Dai, B, Bullock, A, Degterev, A, Cuny, G

2-amino-2, 3-dihydro-1H-indene-5-carboxamide-based discoidin domain receptors 1 (DDR1) inhibitors: design, synthesis, and in vivo anti-pancreatic cancer efficacy 由 Zhu, D, Huang, H, Pinkas, D, Luo, J, Ganguly, D, Fox, A, Arner, E, Xiang, Q, Tu, Z, Bullock, A, Brekken, R, Ding, K, Lu, X

BTB domain mutations perturbing KCTD15 oligomerisation cause a distinctive frontonasal dysplasia syndrome 由 Miller, K, Cruz Walma, D, Pinkas, D, Tooze, R, Bufton, J, Richardson, W, Manning, C, Hunt, A, Cros, J, McGowan, S, Twigg, S, Chalk, R, Staunton, D, Johnson, D, Wilkie, A, Bullock, A

The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms 由 Fulcher, L, Bozatzi, P, Tachie-Menson, T, Wu, K, Cummins, T, Bufton, J, Pinkas, D, Dunbar, K, Shrestha, S, Wood, N, Weidlich, S, Macartney, T, Varghese, J, Gourlay, R, Campbell, D, Dingwell, K, Smith, J, Bullock, A, Sapkota, G

Design, synthesis, and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a dua... 由 Wang, Z, Zhang, Y, Pinkas, D, Fox, A, Luo, J, Huang, H, Cui, S, Xiang, Q, Xu, T, Xun, Q, Zhu, D, Tu, Z, Ren, X, Brekken, R, Bullock, A, Liang, G, Ding, K, Lu, X

With No Lysine Kinase 3 (WNK3); A Target Enabling Package 由 Bullock, A

其他作者: “...Pinkas, D...”